Liminal BioSciences: Down on cancelling some studies for drug candidate Fezagepras

Liminal BioSciences

28/05/2021 22:37

** U.S.-listed shares of Canadian drugmaker  LMNL.O  down
7.6% at $4.08 in extended trading 
    ** Co decides to cancel its plans to move its drug candidate
Fezagepras into Phase II clinical study in Idiopathic Pulmonary
Fibrosis and an early-to-mid stage study in Hypertriglyceridemia
 urn:newsml:reuters.com:*:nPn5k0yTJa
    ** Says decision based on interim data from a study testing
multiple doses of the drug
    ** As of last close, stock had gained ~5% this year

 (Reporting by Tiyashi Datta in Bengaluru)
 ((tiyashi.datta@thomsonreuters.com))